As previously mentioned, DCIS has been characterized as a type of breast cancer with small in size, low grade, and estrogen receptor (ER) and progesterone receptor (PR) positive expression, but HER2 testing is not a routine part of the pathologic evaluation [6, 7]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.